IL17A and Langerhans cell histiocytosis: Mo-DCs from LCH patients were cultured with low doses of toxic compounds in the presence of either isotype control or neutralizing anti-IL-17A antibodies, and then compared to DCs treated with anti-IL-17A antibodies.